Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2292767 in Healthy Smokers
NCT03045887Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2292767 in asthma (10 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE) up to 12 weeks, Number of Participants With Any AE and Any SAE up to 4 weeks and 4 more. Started Feb 2017; status: completed.
02
Drugs
GSK2292767
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03045887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045887.